Inactive Ingredients in Meloxicam Made by Cipla
Based on the available evidence, meloxicam tablets manufactured by Cipla contain magnesium stearate as an inactive ingredient, which has been identified as potentially incompatible with the active ingredient meloxicam 1.
Inactive Ingredients in Meloxicam Tablets
While the specific and complete list of inactive ingredients in Cipla's meloxicam formulation is not explicitly provided in the available evidence, pharmaceutical research indicates that meloxicam formulations typically contain several excipients, with magnesium stearate being a common one that warrants particular attention.
Known Excipients in Meloxicam Formulations:
- Magnesium stearate: Used as a lubricant in tablet manufacturing, but has been identified as potentially incompatible with meloxicam in binary mixtures 1
- Other possible excipients in meloxicam formulations may include common tablet ingredients, though these are not specifically confirmed for Cipla's product in the provided evidence
Clinical Relevance of Excipients
The compatibility between meloxicam and its excipients is particularly important because:
- Meloxicam is a BCS Class II drug, meaning dissolution is the limiting step for its bioavailability 1
- Any changes in formulation or excipient interactions could directly influence the quality and effectiveness of the product 1
- Thermal analysis has shown that meloxicam is incompatible with magnesium stearate, which was confirmed by stress studies and chromatographic analyses 1
Pharmacological Properties of Meloxicam
For context, meloxicam is:
- A non-steroidal anti-inflammatory drug (NSAID) with preferential inhibition of COX-2 2
- Administered once daily due to its 20-hour half-life 3
- Metabolized to 4 pharmacologically inactive metabolites before excretion 3
- Extensively bound to plasma albumin 3
Important Considerations
If you have concerns about specific inactive ingredients in meloxicam:
- Patients with known sensitivities to specific excipients should discuss alternatives with their healthcare provider
- For patients with gastrointestinal concerns, it's worth noting that meloxicam has shown reduced incidence of gastrointestinal side effects compared to some other NSAIDs due to its COX-2 selectivity 2
- Elderly patients should be aware that NSAIDs including meloxicam are listed in the American Geriatrics Society Beers Criteria as potentially inappropriate medications for older adults due to risks of gastrointestinal bleeding and kidney injury 4
If you need the complete and specific list of inactive ingredients in Cipla's meloxicam formulation, consulting the manufacturer's package insert or contacting Cipla directly would provide the most accurate information.